Innovations in Pain Management, Drug Discovery, and Development, as well as Increasing Awareness about surgical interventions, rising investments in healthcare by governments, are some of the driving factors for the Postoperative Pain treatment market.
“Postoperative Pain Pipeline Insight, 2022″ report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postoperative Pain pipeline landscape is provided which includes the disease overview and Postoperative Pain treatment guidelines. The assessment part of the report embraces, in depth Postoperative Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postoperative Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Post-Operative Pipeline Report
- DelveInsight’s Postoperative Pain Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline treatment therapies.
- Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Postoperative Pain treatment scenario include Vivozon, Grunenthal, Apsen Farmaceutica, Trevena, Haisco Pharmaceutical Group, Concentric Analgesics, Unither Pharmaceuticals, Formosa Pharmaceuticals, Cara Therapeutics, Taiwan Liposome Company, Adynxx, Teikoku Pharma USA, Cali Pharmaceuticals, ACADIA Pharmaceuticals, Nevakar, Cytogel, Mati Therapeutics, Allay therapeutics, SiteOne Therapeutics, NeurOp, Flexion Therapeutics, Hefei Cosource Pharmaceutical, Layerbio, Neumentum, Antibe Therapeutics, Serina Therapeutics, InSitu Biologics, PharmaTher, Bexson Biomedical, Hana Pharm, Expanesthetics, Algomedix Inc, AmacaThera, Andros Pharmaceuticals, Heron Therapeutics, Endo Pharmaceuticals, Mylan, Camurus, PainReform, Jiangsu HengRui Medicine, Polypid, Pharmaleads, Nuance Biotech Co, PharmaTher, TSRL, Neumentum Inc., Janssen Pharmaceutica NV, McNeil Consumer Pharmaceuticals Co, and many others.
- Essential Postoperative Pain pipeline therapies such as VVZ-149, Qutenza, TRV130, HSK21542, CA-008, SVT-15473, APP13007, CR845, TLC590, PRF110, OCS-01, MR-107A-01,JNJ-10450232, HR18042, CPL- 01, ACP-044, NVK-009, CYT 1010, XG005, CAM2048, ATX-101, ST 2427, NP 10679, ND-340, FX301,HYR-PB21, LC-400, NTM-001, RHN-002, ATB-352, SER-227, INSB200, BB106, ATX-201, AMT-143, APC401, and others are under development in different phases of clinical trials.
Latest Breakthroughs and Developments in the Post-Operative Treatment Landscape
- In June 2021, Formosa Pharmaceuticals and China Grand Pharma announced that they have entered into an exclusive licensing agreement for the development and commercialization of Formosa’s APP13007 in the territory defined by Mainland China, Hong Kong, and Macau. APP13007, derived from Formosa’s proprietary nanoparticle formulation platform, is a novel ophthalmic application of one of the most potent known corticosteroids for the treatment of inflammation and pain after cataract surgery.
- In October 2021, Neumentum entered into a license agreement with Nuance Biotech Co. Ltd, a China based specialty pharmaceutical company, providing Nuance with the exclusive rights to develop and commercialize Neumentum’s novel ketorolac for IV infusion (NTM-001) in China.
- In January 2021, IACTA Pharmaceuticals, Inc. and Pharmaleads announced they that have entered into licensing agreements, with IACTA acquiring global rights to Pharmaleads’ Dual Enkephalinase Inhibitors (DENKI®), a novel class of non-opioid compounds for the treatment of acute and chronic ocular pain.
- In June 2021, PharmaTher and TSRL entered into a Co-Development Agreement to jointly develop a microneedle array patch with the aim to control the manufacturing and supply of microneedle patches for the Companies respective clinical and commercial drug programs. PharmaTher and TSRL share the commitment to commercialize a patented hydrogel-forming microneedle patch delivery technology licensed from Queens University of Belfast.
- In November 2018, The Food and Drug Administration (FDA) announced fast track status for VVZ-149 (Vivozon Inc), a non-opioid, non-NSAID analgesic for the treatment of pain.
- In September 2018, Concentric Analgesics announced that it had received Breakthrough Therapy designation from the US FDA for CA-008 in post-surgical pain.
- In October 2019, Neumentum Inc. announced that it has entered into a global licensing agreement with Janssen Pharmaceutica NV and McNeil Consumer Pharmaceuticals Co., both part of the Johnson & Johnson Family of Companies, for the rights to a novel oral analgesic, JNJ-10450232, plus a portfolio of backup compounds. Neumentum wants to take JNJ-10450232, which it describes as neither an opioid nor a nonsteroidal anti-inflammatory drug, forward in the treatment of moderate to moderately severe acute pain. The deal, financial details of which were not disclosed. The agreement covers an asset that came through a Phase II pain trial in 2015 only to stall following the completion of the study.
Find out more about the disease and recent developments @ Postoperative Pain Pipeline Assessment
Postoperative Pain Overview
Postoperative Pain are the side effects of cancer chemotherapy that can cause significant negative impacts on patients’ quality of life and on their ability to tolerate and comply with therapy. An estimated 80% of patients with cancer experience chemotherapy-induced nausea and vomiting. It includes emesis and nausea, which can involve a loss of appetite and result in decreased oral intake of fluids and calories. CINV can be classified into 5 types: acute, delayed, anticipatory, breakthrough, and refractory. The pathophysiology of CINV includes both peripheral and central nervous system (CNS) pathways with different mechanisms involved in acute CINV and delayed CINV. Risk factors for developing CINV can be classified as patient-related or treatment-related. Prevention is the primary goal in the management of CINV. The primary alternative for prevention and treatment include 5-HT3 receptor antagonists, NK1 receptor antagonists, and corticosteroids. Other medications used, but to a lesser extent, include dopamine antagonists, benzodiazepines, cannabinoids, and olanzapine.
Postoperative Pain Emerging Drugs
- VVZ-149: Vivozon
- Qutenza: Grunenthal
- CYT-1010: Cytogel Pharma
- ACP-044: ACADIA Pharmaceuticals
- CAM2048: Camurus
- ST 2427: SiteOne Therapeutics
Postoperative Pain Pipeline Therapeutics Analysis
There are approx. 55+ key companies which are developing the therapies for Postoperative Pain. The companies which have their Postoperative Pain drug candidates in the most advanced stage, i.e. Phase III include, Vivozon.
Learn more about the novel and emerging Postoperative Pain pipeline therapies @ Postoperative Pain Pipeline Analysis
DelveInsight’s Postoperative Pain Pipeline Report covers around 55+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Postoperative Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Postoperative Pain Pipeline Molecule types such as-
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Scope of the Postoperative Pain Pipeline Report
- Coverage- Global
- Postoperative Pain Companies- Vivozon, Grunenthal, Apsen Farmaceutica, Trevena, Haisco Pharmaceutical Group, Concentric Analgesics, Unither Pharmaceuticals, Formosa Pharmaceuticals, Cara Therapeutics, Taiwan Liposome Company, Adynxx, Teikoku Pharma USA, Cali Pharmaceuticals, ACADIA Pharmaceuticals, Nevakar, Cytogel, Mati Therapeutics, Allay therapeutics, SiteOne Therapeutics, NeurOp, Flexion Therapeutics, Hefei Cosource Pharmaceutical, Layerbio, Neumentum, Antibe Therapeutics, Serina Therapeutics, InSitu Biologics, PharmaTher, Bexson Biomedical, Hana Pharm, Expanesthetics, Algomedix Inc, AmacaThera, Andros Pharmaceuticals, Heron Therapeutics, Endo Pharmaceuticals, Mylan, Camurus, PainReform, Jiangsu HengRui Medicine, Polypid, Pharmaleads, Nuance Biotech Co, PharmaTher, TSRL, Neumentum Inc., Janssen Pharmaceutica NV, McNeil Consumer Pharmaceuticals Co, and others
- Postoperative Pain Therapies- VVZ-149, Qutenza, TRV130, HSK21542, CA-008, SVT-15473, APP13007, CR845, TLC590, PRF110, OCS-01, MR-107A-01,JNJ-10450232, HR18042, CPL- 01, ACP-044, NVK-009, CYT 1010, XG005, CAM2048, ATX-101, ST 2427, NP 10679, ND-340, FX301,HYR-PB21, LC-400, NTM-001, RHN-002, ATB-352, SER-227, INSB200, BB106, ATX-201, AMT-143, APC401, and others
- Postoperative Pain Therapeutic Assessment by Product Type
- Postoperative Pain Therapeutic Assessment by Stage and Product Type
- Postoperative Pain Therapeutic Assessment by Route of Administration
- Postoperative Pain Therapeutic Assessment by Stage and Route of Administration
- Postoperative Pain Therapeutic Assessment by Molecule Type
- Postoperative Pain Therapeutic Assessment by Stage and Molecule Type
- Postoperative Pain companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Postoperative Pain – Market Drivers and Barriers
- Postoperative Pain – Future Perspectives and Conclusion
Table of Content
- Introduction
- Executive Summary
- Postoperative Pain: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Postoperative Pain – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Postoperative Pain Collaboration Deals
- Late Stage Products (Phase III)
- VVZ-149: Vivozon
- Mid Stage Products (Phase II)
- TLC590: Taiwan Liposome Company
- Early Stage Products (Phase I)
- ST 2427: SiteOne Therapeutics
- Preclinical and Discovery Stage Products
- INSB200: InSitu Biologics
- Inactive Products
- Postoperative Pain Key Companies
- Postoperative Pain Key Products
- Postoperative Pain- Unmet Needs
- Postoperative Pain- Market Drivers and Barriers
- Postoperative Pain- Future Perspectives and Conclusion
- Postoperative Pain Analyst Views
- Postoperative Pain Key Companies
- Appendix
For further information on the Postoperative Pain Pipeline therapeutics, reach out to Postoperative Pain Drugs
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/